Search Within

Gunjan Lalitchandra Shah

Formats
  1. Meeting Abstract (290)
  2. Journal Article (128)
  3. Research Letter (15)
  4. Review (6)
  5. Correspondence (2)
  6. Guidelines (1)
Groups
  1. Bone Marrow Transplant (442)
  2. Center for Hematologic Malignancies (442)
  3. Department of Medicine (442)
  4. Hematologic Malignancies, Division of (442)
  5. Survivorship Research (442)
  6. CTCR Scholars (340)

More Groups

People
  1. Sergio Giralt (308)
  2. Michael Scordo (295)
  3. Miguel-Angel Perales (203)
  4. Sean Devlin (187)
  5. Parastoo Dahi (163)
  6. Heather Landau (161)

More People

Years
  1. 2025 (18)
  2. 2024 (72)
  3. 2023 (85)
  4. 2022 (55)
  5. 2021 (31)
  6. 2020 (51)

More Years

Publications
  1. Blood (155)
  2. Biology of Blood and Marrow Transplantation (73)
  3. Clinical Lymphoma, Myeloma and Leukemia (39)
  4. Transplantation and Cellular Therapy (23)
  5. Blood Advances (21)
  6. Bone Marrow Transplantation (19)

More Publications

Publishers
  1. American Society of Hematology (176)
  2. Elsevier Inc. (142)
  3. Nature Publishing Group (32)
  4. American Society of Clinical Oncology (15)
  5. Taylor & Francis Group (9)
  6. Wiley Blackwell (7)

More Publishers

Results (442)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Outcomes for patients with relapsed and refractory peripheral T-cell lymphoma in the 21st century by relapse status, salvage therapy, and receipt of allogeneic transplant
    Meeting Abstract

    Stuver, R.; Epstein-Peterson, Z. D.; Johnson, W. T.; Khan, N.; Sauter, C. S.; Scordo, M.; Shah, G. L.; Moskowitz, A. J.; Horwitz, S. M.
    Blood (2022)

    Fulltext@MSK | Save
  • Hospital costs and healthcare resource utilization (HRU) for chimeric antigen (CAR) T-cell therapy and stem cell transplant (SCT) in patients with large B-cell lymphoma (LBCL) in the United States (US)
    Meeting Abstract

    Cui, C.; Feng, C.; Rosenthal, N.; Wade, S. W.; Curry, L.; Fu, C.; Shah, G. L.
    Blood (2022)

    Fulltext@MSK | Save
  • Carfilzomib, lenalidomide and dexamethasone (KRd) vs bortezomib, lenalidomide, and dexamethasone (VRd) as induction therapy in newly diagnosed high-risk multiple myeloma
    Meeting Abstract

    Tan, C.; Nemirovsky, D.; Derkach, A.; Hultcrantz, M.; Hassoun, H.; Mailankody, S.; Shah, U. A.; Patel, D.; Maclachlan, K. H.; Lahoud, O. B.; more...
    Blood (2022)

    Fulltext@MSK | Save
  • Real-world outcomes for patients with relapsed or refractory (R/R) aggressive B-cell non-Hodgkin's lymphoma (aBNHL) treated with commercial tisagenlecleucel: Subgroup analyses from the Center for International Blood and Marrow Transplant Research (CIBMTR) registry
    Meeting Abstract

    Landsburg, D. J.; Frigault, M.; Heim, M.; Foley, S. R.; Hill, B. T.; Ho, C. M.; Jacobson, C. A.; Jaglowski, S.; Locke, F. L.; Ram, R.; more...
    Blood (2022)

    Fulltext@MSK | Save
  • A phase 2 study of pembrolizumab (MK-3475) after autologous stem cell transplantation in patients with T-cell non-Hodgkin lymphoma
    Meeting Abstract

    Merrill, M. H.; Dahi, P. B.; Redd, R. A.; McDonough, M. M.; Chen, Y. B.; LaCasce, A. S.; Fisher, D. C.; Herrera, A. F.; Jacobson, C. A.; Kim, A. I.; more...
    Blood (2022)

    Fulltext@MSK | Save
  • Genomic determinants of resistance in newly diagnosed multiple myeloma treated with targeted-immunotherapy
    Meeting Abstract

    Maura, F.; Boyle, E.; Coffey, D.; Maclachlan, K. H.; Diamond, B.; Blaney, P.; Gagler, D.; Ziccheddu, B.; Ghamlouch, H.; Wang, Y.; more...
    Blood (2022)

    Fulltext@MSK | Save
  • Analysis of 372 adult allograft recipients reveals associations between non-European ancestry, low socioeconomic status, and receipt of HLA-disparate grafts
    Meeting Abstract

    Fingrut, W.; Chinapen, S.; Katrichis, A.; Carino, C.; Davis, E.; Shaffer, B. C.; Cho, C.; Shah, G. L.; Barker, J. N.
    Blood (2022)

    Fulltext@MSK | Save
  • Fc-mediated antibody effector function, inflammation resolution and oligoclonality on TCR rearrangements predict sustained MRD negativity in newly diagnosed multiple myeloma treated with immunotherapy regimens
    Meeting Abstract

    Boyle, E. M.; Maura, F.; Coffey, D.; Maclachlan, K. H.; Diamond, B.; Ghamlouch, H.; Gagler, D.; Blaney, P.; Ziccheddu, B.; Wang, Y.; more...
    Blood (2022)

    Fulltext@MSK | Save
  • Inflammatory biomarker clusters are predictive of response and toxicity in large B-cell lymphoma treated with CD19 CAR-T cell therapy
    Meeting Abstract

    Raj, S.; Perales, M. A.; Fein, J. A.; Tomas, A. A.; Batlevi, C. L.; De Lapuerta, M. C.; Dahi, P. B.; Danylesko, I.; Fried, S.; Funnell, T.; more...
    Blood (2022)

    Fulltext@MSK | Save
  • Stem cell autograft minimal residual disease negativity improves outcomes after autotransplant for multiple myeloma
    Meeting Abstract

    Nishimura, N.; Brown, S.; Devlin, S. M.; Dahi, P. B.; Landau, H.; Lahoud, O. B.; Scordo, M.; Shah, G. L.; Hassoun, H.; Hultcrantz, M.; more...
    Blood (2022)

    Fulltext@MSK | Save